semaglutide hepatotoxicity case report Tirzepatide-Induced Liver Injury: A Rare Complication Semaglutide in MASLD Patients: Improved

After 104 weeks of treatment, the primary outcome of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke occurred in 6.6% of the patients in the semaglutide group and 8.9% of those in the placebo group, resulting in a hazard ratio (HR) of 0.74 (95% CI 0.580.95) [13]

MJB: Writingreview & editing

Testosterone optimization during weight loss phases produces dramatically better outcomes than caloric restriction alone

1,000, 299 499

While dairy can offer significant benefits through probiotics, calcium, and bioactive peptides, potential risks such as lactose intolerance, allergies, and gut inflammation should not be overlooked